POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
This disclosure relates to delivery vehicles comprising payload molecules, e.g., mRNA or gene editing therapeutics for the treatment of cystic fibrosis (CF). Nucleic acid therapeutics (e.g., mRNAs) for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR). Nucleic acid therapeutics (e.g., mRNAs) of the disclosure increase and/or restore deficient levels of CFTR expression and/or activity in subjects. Nucleic acid therapeutics (e.g., mRNAs) of the disclosure further decrease abnormal accumulation of ammonia associated with deficient CFTR activity in subjects.
1 . A messenger RNA (mRNA) comprising an open reading frame (ORF) encoding the cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide of SEQ ID NO:1, wherein the ORF is at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to the nucleotide sequence of SEQ ID NO:142.
2 . The mRNA of claim 1 , wherein the mRNA comprises a 5′ untranslated region (UTR) comprising the nucleotide sequence of SEQ ID NO:25.
3 . The mRNA of claim 1 , wherein the mRNA comprises a 5′ UTR comprising the nucleotide sequence of SEQ ID NO:24.
4 . A messenger RNA (mRNA) comprising a 5′ untranslated region (UTR) comprising the nucleotide sequence of SEQ ID NO:28 and an open reading frame (ORF) encoding the cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide of SEQ ID NO:1.
5 . The mRNA of claim 4 , wherein the 5′ UTR comprises the nucleotide sequence of SEQ ID NO:25.
6 . The mRNA of claim 4 , wherein the 5′ UTR comprises the nucleotide sequence of SEQ ID NO:24.
7 . The mRNA of any one of claims 1 to 6 , wherein the mRNA comprises a 3′ UTR comprising the nucleotide sequence of SEQ ID NO:45.
8 . A messenger RNA (mRNA) comprising a 3′ untranslated region (UTR) comprising the nucleotide sequence of SEQ ID NO:45 and an open reading frame (ORF) encoding the cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide of SEQ ID NO:1.
9 . The mRNA of claim 8 , wherein the mRNA comprises a 5′ UTR comprising the nucleotide sequence of SEQ ID NO:28.
10 . The mRNA of claim 8 , wherein the mRNA comprises a 5′ UTR comprising the nucleotide sequence of SEQ ID NO:24 or 25.
11 . The mRNA of any one of claims 1 to 10 , wherein the mRNA comprises a 5′ terminal cap comprising m 7 G-ppp-Gm-AG.
12 . The mRNA of any one of claims 1 to 11 , wherein the mRNA comprises a poly-A region comprising A100-UCUAG-A20-inverted deoxy-thymidine (SEQ ID NO:211).
13 . The mRNA of any one of claims 1 to 12 , comprising the nucleotide sequence of SEQ ID NO:153.
14 . A messenger RNA (mRNA) comprising:
(i) a 5′ terminal cap comprising m 7 G-ppp-Gm-AG;
(ii) a 5′ untranslated region (UTR) comprising the nucleotide sequence of SEQ ID NO:25;
(iii) an open reading frame (ORF) encoding the cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide of SEQ ID NO:1, wherein the ORF comprises the nucleotide sequence of SEQ ID NO:142;
(iv) a 3′ UTR comprising the nucleic acid sequence of 45; and
(v) a poly-A region comprising A100-UCUAG-A20-inverted deoxy-thymidine (SEQ ID NO:211).
15 . The mRNA of any one of claims 1 to 14 , wherein the mRNA comprises at least one chemically modified nucleobase, sugar, backbone, or any combination thereof.
16 . The mRNA of any one of claims 1 to 14 , wherein all of the uracils of the mRNA are N1-methylpseudouracils.
17 . A pharmaceutical composition comprising the mRNA of any one of claims 1 to 16 .
18 . A lipid nanoparticle comprising the mRNA of any one of claims 1 to 16 .
19 . The lipid nanoparticle of claim 18 , wherein the lipid nanoparticle comprises:
a lipid nanoparticle core comprising:
(i) an ionizable lipid,
(ii) a phospholipid,
(iii) a structural lipid, and
(iv) a PEG-lipid, and
wherein the mRNA is encapsulated within the core, and
wherein the lipid nanoparticle core has been contacted with a cationic agent.
20 . The lipid nanoparticle of claim 19 , wherein the cationic agent is GL-67:
or a salt thereof.
21 . The lipid nanoparticle of claim 18 , wherein the lipid nanoparticle comprises:
(i) an ionizable lipid,
(ii) a phospholipid;
(iii) a structural lipid;
(iv) a PEG-lipid; and
(v) a cationic agent.
22 . The lipid nanoparticle of claim 21 , wherein the cationic agent is a sterol amine.
23 . The lipid nanoparticle of claim 21 , wherein the cationic agent is GL-67:
or a salt thereof.
24 . A lipid nanoparticle comprising:
(i)
or a salt thereof;
(ii)
or a salt thereof; and
(iii) a messenger RNA (mRNA) encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide.
25 . The lipid nanoparticle of claim 24 , wherein the CFTR polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1.
26 . A process of preparing a nanoparticle comprising contacting a lipid nanoparticle core with a cationic agent, wherein the lipid nanoparticle comprises:
(a) a lipid nanoparticle core comprising:
(i) an ionizable lipid,
(ii) a phospholipid,
(iii) a structural lipid, and
(iv) a PEG-lipid, and
(b) the mRNA of any one of claims 1 to 16 .
27 . The process of claim 26 , wherein the contacting of the lipid nanoparticle core with a cationic agent comprises dissolving the cationic agent in a non-ionic excipient.
28 . The process of claim 27 , wherein the non-ionic excipient is macrogol 15 hydroxystearate (HS 15).
29 . The process of any one of claims 25 to 28 , wherein the cationic agent is a sterol amine.
30 . The process of claim 29 , wherein the sterol amine is GL-67:
or a salt thereof.
31 . A nanoparticle prepared by the process of any one of claims 26 - 30 .
32 . A method of treating or preventing cystic fibrosis in a human subject in need thereof, comprising administering to the subject the mRNA of any one of claims 1 to 16 , the pharmaceutical composition of claim 17 , the lipid nanoparticle of any one of claims 18 to 25 , or the nanoparticle of claim 31 .
33 . A method of preventing cystic fibrosis in a human subject having cystic fibrosis-causing mutations in both copies of the CFTR gene, comprising administering to the subject the mRNA of any one of claims 1 to 16 , the pharmaceutical composition of claim 17 , the lipid nanoparticle of any one of claims 18 to 25 , or the nanoparticle of claim 31 .
34 . The method of claim 33 , wherein the cystic fibrosis-causing mutations are selected from the group consisting of G542X, W1282X, R553X, F508del, N1303K, I507del, G551D, S549N, D1152H, R347P, and R117H.
35 . The method of any one of claims 32 to 34 , wherein the administering is to the respiratory tract or lung of the subject.